<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Upper respiratory tract infections: Considerations in adolescent and adult athletes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Upper respiratory tract infections: Considerations in adolescent and adult athletes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Upper respiratory tract infections: Considerations in adolescent and adult athletes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie A Jaworski, MD, FAAFP, FACSM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Pyne, PhD, FACSM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francis G O'Connor, MD, MPH, FACSM, FAMSSM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Grayzel, MD, FAAEM</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4395052"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Upper respiratory tract infections (URTIs) are common in athletes. The majority are self-limited viral infections. The evaluation and treatment of athletes with URTIs is typically the same as in the general population. However, there are specific considerations for medication choices in athletes and clinicians may be asked to determine when an athlete can return to play or competition.</p><p>This topic will discuss the epidemiology, evaluation, and specific medication considerations in athletes with URTI. It will also discuss how to determine when an athlete can return to play after URTI.</p><p class="headingAnchor" id="H357309978"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>For the purposes of this topic, "athlete" refers to adolescents and adults who participate in both recreational and competitive sports.</p><p>The term "upper respiratory tract infection" may be used to describe a variety of infections. For the purposes of this topic, URTIs include the illnesses listed below. Information regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections is provided separately. </p><p class="bulletIndent1"><span class="glyph">●</span>The common cold (see  <a class="medical medical_review" href="/d/html/6865.html" rel="external">"The common cold in adults: Diagnosis and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6868.html" rel="external">"The common cold in adults: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/5978.html" rel="external">"The common cold in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious mononucleosis (see  <a class="medical medical_review" href="/d/html/8318.html" rel="external">"Infectious mononucleosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza (see  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5985.html" rel="external">"Seasonal influenza in children: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pertussis (see  <a class="medical medical_review" href="/d/html/8045.html" rel="external">"Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharyngitis (see  <a class="medical medical_review" href="/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults"</a> and  <a class="medical medical_review" href="/d/html/14610.html" rel="external">"Symptomatic treatment of acute pharyngitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6457.html" rel="external">"Evaluation of sore throat in children"</a> and  <a class="medical medical_review" href="/d/html/5971.html" rel="external">"Group A streptococcal tonsillopharyngitis in children and adolescents: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2875.html" rel="external">"Acute pharyngitis in children and adolescents: Symptomatic treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinusitis (see  <a class="medical medical_review" href="/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/6069.html" rel="external">"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5999.html" rel="external">"Acute bacterial rhinosinusitis in children: Microbiology and management"</a>)</p><p></p><p class="headingAnchor" id="H20838731"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Upper respiratory tract infections (URTIs) are the most common type of infection in athletes [<a href="#rid1">1,2</a>]. In general, the incidence in athletes is the same as nonathletes. In the majority of cases, URTIs are self-limited viral infections [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4395175"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>There is little evidence that the incidence of URTI varies by sport. However, athletes in some sports are at higher risk for viral illnesses, such as influenza and infectious mononucleosis, as a consequence of close contact with teammates and opponents. URTIs are the most common cause of illness at national and international sporting competitions, likely related to increased exposure to pathogens during both travel and competition [<a href="#rid1">1,4,5</a>]. Risks associated with COVID-19 infection and spread are discussed separately. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.) </p><p>Athletes appear to be at greater risk of infection during the winter months [<a href="#rid6">6,7</a>]. This likely has to do with the seasonal variations of pathogens that cause URTIs (eg, influenza), as well as increased indoor crowding [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/7006.html" rel="external">"Influenza: Epidemiology and pathogenesis"</a>.)</p><p>International travel across more than five time zones is associated with an increased risk of illness [<a href="#rid7">7-9</a>]. Such risk appears to be highest the day after travel. Other factors associated with increased risk include sleep disturbances, severe psychosocial stress, a major personal crisis, or an imbalance between psychological stress and recovery [<a href="#rid7">7-9</a>]. Preliminary studies suggest an increased risk of URTIs among athletes with reduced serum vitamin D concentrations or lower salivary IgA measurements [<a href="#rid7">7</a>].</p><p>A small number of athletes experience persistent or recurrent URTIs. The athletes most at risk are those who participate in high-intensity training, including both speed and strength training, or who undertake high loads continuously over weeks to months with insufficient recovery [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/97059.html" rel="external">"Overtraining syndrome in athletes"</a>.)</p><p class="headingAnchor" id="H20838737"><span class="h2">Relationship to exercise</span><span class="headingEndMark"> — </span>The relationship between infection and exercise is poorly understood [<a href="#rid10">10,11</a>]. The risk of illness appears to increase with prolonged and/or intensive training, especially in susceptible athletes (eg, poorly-controlled asthmatics, those with chronic disease, those who are immunosuppressed, or those who have had a recent infection) [<a href="#rid12">12</a>]. However, most athletes can exercise, train, and compete with confidence, as acute exercise more likely improves rather than compromises immune competency [<a href="#rid13">13</a>].</p><p>A number of models have been developed to characterize relationships between the volume/intensity of exercise (and training) and risk of URTI. The J-curve model is based on evidence that moderately active individuals typically have a lower risk of URTI compared with sedentary individuals, but some highly trained athletes have a paradoxically heightened risk [<a href="#rid14">14</a>]. Another model is the open window theory, where the immune system is temporarily down-regulated in the hours after strenuous exercise or training leading to a 'window' of opportunity for infections to become established [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H91274813"><span class="h2">Effect on competition performance</span><span class="headingEndMark"> — </span>Infections that coincide with the preparations for or actual competition may impair performance if the symptoms are moderate to severe. For example, the prolonged cough experienced by those with pertussis can hamper athletic performance [<a href="#rid3">3</a>].</p><p>Infections occurring early in the season well away from competition are unlikely to have substantial effects on competitive performance, unless a significant amount of training time is lost. In a retrospective study of 69 swimmers, mild infections (predominantly URTIs) lasting two or more days in the six weeks prior to international competition had little adverse effect on performance [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4395817"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of athletes for the various etiologies of upper respiratory tract infections (URTIs) is the same as for the general population. Evaluation and screening for coronavirus disease 2019 (COVID-19) will likely vary by sport and local conditions. </p><p>Although it is not always necessary to obtain a white blood cell count (WBC) in the evaluation of URTI, exercise appears to affect WBC counts and function. The clinical importance of these changes is unclear. Prolonged endurance training can lead to leukopenia, but this is likely not pathologic. In one study including over 900 females and 1300 males in 14 sports, 16 percent of athletes who participated in aerobic sports (eg, cycling or the triathlon) had WBC counts that were below the normal reference range [<a href="#rid17">17</a>]. Also, acute exercise will typically increase the numbers of circulating leukocytes, but changes are transient and likely of little clinical significance. (See  <a class="medical medical_review" href="/d/html/8381.html" rel="external">"Approach to the patient with neutrophilia", section on 'Stress/exercise'</a>.)</p><p class="headingAnchor" id="H92871205"><span class="h1">MEDICATION CONSIDERATIONS</span><span class="headingEndMark"> — </span>In general, treatment strategies for upper respiratory tract illnesses (URTIs) in athletes should be the same as for nonathletes. There are some specific considerations for athletes regarding choice of antibiotics and adjunctive medications.</p><p class="headingAnchor" id="H92871211"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>The same criteria should be used to determine if antibiotic treatment is necessary in athletes as in nonathletes. However, certain antibiotics have adverse effects that may have implications for athletes  (<a class="graphic graphic_table graphicRef102914" href="/d/graphic/102914.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoroquinolones </strong>–<strong> </strong>When other options are available, we avoid prescribing fluoroquinolones in athletes because they are associated with tendinopathy and tendon rupture [<a href="#rid18">18,19</a>]. When fluoroquinolones are the best option for treatment, we monitor athletes for tendon pain. Any athlete that develops tendon pain while on fluoroquinolones should stop the medication and seek prompt evaluation. (See  <a class="medical medical_review" href="/d/html/190.html" rel="external">"Achilles tendinopathy and tendon rupture", section on 'Epidemiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Tendinopathy'</a>.)</p><p></p><p class="bulletIndent1">In addition, fluoroquinolones are associated with photosensitivity and QT prolongation, which have specific implications for athletes [<a href="#rid19">19</a>]. In athletes that use fluoroquinolones, we recommend precautions such as sunscreen and protective clothing, particularly if they participate in outdoor sports. Some athletes are evaluated with an electrocardiogram (ECG) as part of clearance for participation. If an athlete needs ECG testing around the time of antibiotic therapy, it is reasonable to avoid the use of fluoroquinolones when possible. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'QT interval prolongation'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Other adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrolides </strong>–<strong> </strong>The potential adverse effects of macrolides include QT prolongation. Some athletes are evaluated with an ECG as part of clearance for participation. If an athlete needs ECG testing around the time of antibiotic therapy, it is reasonable to avoid the use of macrolides when possible [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'QT interval prolongation and cardiovascular events'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'QT interval prolongation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tetracyclines and sulfonamides</strong> – Side effects of both of these antibiotics include photosensitivity. If these antibiotics are used, we recommend precautions such as sunscreen and protective clothing, particularly if athletes participate in outdoor sports [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a> and  <a class="medical medical_review" href="/d/html/494.html" rel="external">"Tetracyclines", section on 'Allergic and skin reactions'</a>.)</p><p></p><p>In addition, any antibiotic may have the following side effects that can affect athletes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic-associated diarrhea </strong>–<strong> </strong>Antibiotic-associated diarrhea is a common side effect that can impair an athlete's performance and increase the risk of dehydration. As with all patients, when possible, we choose narrow spectrum antibiotics and avoid extended courses [<a href="#rid19">19</a>]. Probiotics in the prevention of antibiotic-associated diarrhea are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases", section on 'C. difficile infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatigue </strong>–<strong> </strong>Antibiotic use in athletes has been associated with fatigue and impaired performance; however, only limited evidence exists to substantiate this claim [<a href="#rid19">19</a>]. Determining if the fatigue is from illness versus the medication can be difficult. If there is concern that antibiotics may be causing fatigue, when possible, we time the antibiotic to avoid dosing around the time of competition or an important event (eg, stopping antibiotics for acne prophylaxis).</p><p></p><p class="headingAnchor" id="H92871399"><span class="h2">Medications used for symptom relief</span><span class="headingEndMark"> — </span>Some medications used for symptom relief (adjunctive medications) may contain banned substances (eg, decongestants) and should be avoided  (<a class="graphic graphic_table graphicRef102914" href="/d/graphic/102914.html" rel="external">table 1</a>). The clinician should refer to the appropriate governing body based on the athlete's sport for information about regulations on banned substances. These agencies include the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wada-ama.org%2F&amp;token=LyMsj877A%2Fv8KGeom5Z8pbuJlgPK4h1FbmaPFWrciGegdkKGLT52ftWE41CIC0eb&amp;TOPIC_ID=13806" target="_blank">World Anti-Doping Agency (WADA)</a> (see prohibited substances <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wada-ama.org%2Fen%2Fprohibited-list&amp;token=LyMsj877A%2Fv8KGeom5Z8pa8h4V2YuwJyT2l%2B3U%2FQDAj%2BtR7kQKw%2Bf49nhaBQ7ZmyyuOkg3HeYe8jR0OMPa0VfA%3D%3D&amp;TOPIC_ID=13806" target="_blank">list</a>) and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.olympic.org%2Ffight-against-doping%2Fdocuments-reports-studies-publications&amp;token=Vep6yX%2FNVSjwuJPOwatRiBGJjWgSDmsrzlSroedRod2TRgB4BE0z98l6JOYze7qsVG1B2c%2FoBRjOnrBBoZm63P0rw0xIb3h0%2BccOk%2BUX1Xs%3D&amp;TOPIC_ID=13806" target="_blank">International Olympic Committee (IOC)</a> [<a href="#rid20">20</a>]. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncaa.org%2Fhealth-and-safety%2Fpolicy%2F2014-15-ncaa-banned-drugs&amp;token=2NxitmAbW6CWZXcDDHRe22uiHIPeXaQQrC%2FLHmqvqOEo3OHBW28Wm4G52N7TKZfeLBCS%2BSVvdlsZ9f0xGxs3ArRh9BJ1u773EakCgZVmeRM%3D&amp;TOPIC_ID=13806" target="_blank">National Collegiate Athletic Association (NCAA)</a> has its own listing for American collegiate athletes [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/7475.html" rel="external">"Use of androgens and other hormones by athletes", section on 'Banned drugs'</a>.)</p><p>Expectorants (eg, <a class="drug drug_general" data-topicid="8503" href="/d/drug information/8503.html" rel="external">guaifenesin</a>) are typically well-tolerated and can help to loosen and thin mucus production. Antihistamines, antitussives, and oral decongestants can have side effects that are harmful for athletes  (<a class="graphic graphic_table graphicRef102914" href="/d/graphic/102914.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Use of first-generation antihistamines (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) can increase risk of heat illness and dehydration due to anticholinergic effects. They can also cause sedation. Second-generation antihistamine formulations are less sedating but can still be dehydrating. Athletes may be more susceptible to injury when using sedating medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some antitussives (eg, <a class="drug drug_general" data-topicid="8893" href="/d/drug information/8893.html" rel="external">dextromethorphan</a>) may cause fatigue and should be used with caution in athletes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral decongestants are associated with a risk of dehydration and hyperthermia in athletes [<a href="#rid3">3</a>].</p><p></p><p>Bronchodilators may be needed for short-term relief of URI-associated bronchospasm. Occasional use of an inhaled, short-acting beta-agonist is usually all that is required. Athletes and coaches should note that beta-agonists are not permitted in some sports due to their potential ergogenic effects. If the need for treatment with such medications persists, they should check with the organizations that supervise drug testing for their sport. The management of exercise-related bronchoconstriction is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p class="headingAnchor" id="H92871462"><span class="h2">Medication and competition</span><span class="headingEndMark"> — </span>Unless necessary, we do not start new medications one or two days prior to competition as side effects cannot always be predicted. Other medications we avoid in competition include  (<a class="graphic graphic_table graphicRef102914" href="/d/graphic/102914.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Antipyretics – These should not be used to mask fevers in order to allow participation.</p><p class="bulletIndent1"><span class="glyph">●</span>Sedating medications – These may make the athlete more susceptible to injury from decreased alertness. (See <a class="local">'Medications used for symptom relief'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Adjunctive medications – Those that contain banned substances should not be used. (See <a class="local">'Medications used for symptom relief'</a> above.)</p><p></p><p>Some question exists whether antibiotics cause fatigue. When possible, we time the prescription of antibiotics as far from competition as possible. (See <a class="local">'Antibiotics'</a> above.)</p><p class="headingAnchor" id="H20838749"><span class="h1">CLEARANCE FOR SPORTS</span></p><p class="headingAnchor" id="H4397783"><span class="h2">General participation</span><span class="headingEndMark"> — </span>Athletes with mild, viral upper respiratory tract infections (URTIs) not involving coronavirus disease 2019 (COVID-19) or other highly contagious pathogens can continue to play as long as they feel able  (<a class="graphic graphic_algorithm graphicRef103349" href="/d/graphic/103349.html" rel="external">algorithm 1</a>) [<a href="#rid22">22</a>]. Athletes may be more susceptible to dehydration during or after a URTI. For this reason, we advise athletes to stay well-hydrated after returning to play, particularly if the athlete plans on participating in their sport/activity at high altitude or in adverse weather conditions [<a href="#rid23">23</a>]. </p><p>Athletes with pre-existing conditions and/or moderate to severe illness (fever or systemic symptoms) may need to refrain from play until such symptoms have resolved. There may be particular considerations for return to play in specific situations. (See <a class="local">'Special circumstances'</a> below and <a class="local">'Preventing spread of infection'</a> below.)</p><p class="headingAnchor" id="H354090073"><span class="h3">Criteria</span><span class="headingEndMark"> — </span>Clinicians can use the "neck check" as a way to determine if athletes can return to play immediately or not  (<a class="graphic graphic_algorithm graphicRef103349" href="/d/graphic/103349.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Passes the neck check </strong>–<strong> </strong>The "neck check" is a widely used screening method for determining appropriateness for participation in sports while ill [<a href="#rid3">3</a>]. Athletes may return to sport if their symptoms are all "above the neck" (eg, rhinorrhea or sore throat) [<a href="#rid24">24</a>]. If there are symptoms present "below the neck" (eg, fever, malaise, chest congestion, or gastrointestinal symptoms), athletes should be kept from participation until symptoms have resolved. Cough may be an "above" or "below" the neck symptom depending on its etiology. For example, if cough is from post-nasal drip, it is "above the neck," but if from pneumonia, it is "below the neck."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever or systemic signs (presumed viral illness) </strong>–<strong> </strong>When fever or other systemic signs of illness are present from presumed viral illness, the athlete should refrain from exercise. Clearance is contingent on the athlete testing negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), afebrile, off antipyretics for a minimum of one day, well-hydrated, and feeling physically ready to return to sport.</p><p></p><p class="bulletIndent1">Athletes with viral illnesses should also refrain from exercise if he or she has unexplained sinus tachycardia. Unexplained sinus tachycardia may be the only sign of myocarditis, an uncommon complication of URTI caused by certain viruses (historically, the most common of which included coxsackie B virus, adenovirus, and Epstein-Barr virus  (<a class="graphic graphic_table graphicRef56995" href="/d/graphic/56995.html" rel="external">table 2</a>)). Potential cardiac involvement of SARS-CoV 2 is discussed separately. (See  <a class="medical medical_review" href="/d/html/129342.html" rel="external">"COVID-19: Cardiac manifestations in adults"</a> and  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a>.)</p><p></p><p class="bulletIndent1">Athletes with unexplained sinus tachycardia following viral URTI should be evaluated promptly if they develop symptoms or signs of myocarditis  (<a class="graphic graphic_table graphicRef66776" href="/d/graphic/66776.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/4933.html" rel="external">"Myocarditis: Causes and pathogenesis", section on 'Viral or "idiopathic" myocarditis'</a> and  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial illness</strong> – Athletes being treated for bacterial illnesses should be afebrile off antipyretics and on antibiotics for at least 24 hours prior to returning to activity. They should also be well-hydrated and feel physically ready to return to play. </p><p></p><p class="headingAnchor" id="H357309417"><span class="h3">Transition back to play</span><span class="headingEndMark"> — </span>Transition back to play depends on the anatomic location, severity of illness, and resolution of symptoms [<a href="#rid25">25</a>]. Return to play following COVID-19 infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/130803.html" rel="external">"COVID-19: Return to sport or strenuous activity following infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Returning after passing the "neck check" </strong>–<strong> </strong>If an athlete passes the "neck check," they should be counseled to initially attempt only 10 to 15 minutes of light exercise or training. If they feel well during this initial trial, they may proceed with exercise as tolerated. Anecdotally, some athletes report that light exercise provides symptomatic relief and an opportunity to clear the sinuses and airways of phlegm and mucus. If an athlete is not able to tolerate light exercise, they should rest and try again the following day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Returning after non-COVID-19 fever or systemic illness </strong>–<strong> </strong>When the athlete returns to play, they should start with light activity and follow a graded return to play based on their response [<a href="#rid9">9</a>]. Typically, the sequence of training increments should be increasing frequency first, then duration, and finally, intensity of exercise. The exact time course will depend on the severity and duration of the underlying infection. A general rule is for every day missed due to illness, the athlete needs two to three days of graded return (eg, if an athlete misses two days of practice due to illness, they should gradually increase activity over four to six days until they are back to normal practice). Increments in training volume and intensity should be limited to approximately 10 percent at a time to avoid overexertion in the early phase of return.</p><p></p><p class="bulletIndent1">In certain situations, it may be appropriate to allow modified participation in sport while an athlete recovers from a URTI. For example, the athlete may be allowed to shoot free throws at basketball practice away from the team if they are afebrile but still recovering from "below the neck" symptoms.</p><p></p><p class="headingAnchor" id="H610041056"><span class="h2">Return to competition</span><span class="headingEndMark"> — </span>Clearance for competition is the same as for general sports participation. Athletes with mild viral URTIs can compete as long as they feel able. An athlete should be held from competition if they have fever or systemic signs of illness in order to prevent more significant illness and avoid the spread of disease. Fever, hypoxia, and dehydration are absolute contraindications to participation. Relative contraindications include the athlete not feeling physically able to participate and infection with an illness that is highly contagious (eg, influenza or pertussis). (See <a class="local">'General participation'</a> above and <a class="local">'Influenza'</a> below and <a class="local">'Pertussis'</a> below.)</p><p class="headingAnchor" id="H20838755"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H1398560921"><span class="h3">COVID-19</span><span class="headingEndMark"> — </span>The presentation and management of athletes infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not differ from the general population. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p>Return to play following COVID-19 infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/130803.html" rel="external">"COVID-19: Return to sport or strenuous activity following infection"</a>.)</p><p class="headingAnchor" id="H4397165"><span class="h3">Infectious mononucleosis</span><span class="headingEndMark"> — </span>Return to sports after infectious mononucleosis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8318.html" rel="external">"Infectious mononucleosis", section on 'Return to sports'</a>.)</p><p class="headingAnchor" id="H92872166"><span class="h3">Underlying respiratory conditions</span><span class="headingEndMark"> — </span>The athlete with poorly-controlled underlying respiratory conditions, such as asthma or chronic obstructive pulmonary disease, should seek the advice of their clinician before reinitiation of activity. (See  <a class="medical medical_review" href="/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H357310749"><span class="h3">SCUBA diving</span><span class="headingEndMark"> — </span>Athletes need to be clear of URTI symptoms for a minimum of 10 days prior to resuming SCUBA diving due to the risk of hypercarbia and lung injury/pneumothorax during ascent. It is also a contraindication to dive with ruptured tympanic membranes [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/177.html" rel="external">"Complications of SCUBA diving", section on 'Barotrauma'</a>.)</p><p class="headingAnchor" id="H20838787"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H92871602"><span class="h2">Preventing spread of infection</span><span class="headingEndMark"> — </span>Upper respiratory tract infections (URTIs) are often very contagious and may spread through athletic teams quickly. Athletes with URTIs should follow precautions to help prevent spread of infection. Moreover, there are specific considerations to prevent the spread of infection for influenza and pertussis.</p><p class="headingAnchor" id="H621675337"><span class="h3">General measures</span><span class="headingEndMark"> — </span>Implementing simple precautions can minimize the spread of URTI among athletic teams [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hand hygiene can reduce transmission of organisms  (<a class="graphic graphic_table graphicRef77676" href="/d/graphic/77676.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All team members should be educated on the importance of coughing etiquette and disposal of soiled tissues. Patient information flyers are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fpdf%2Fprotect%2Fcdc_cough.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDNCQ%2FHk1NxdBjbXZAZh4MH2N7C%2Btd5pMRlGJrMNFXVz2fNP%2FxoOERw0tc%2BiP17cNA%3D%3D&amp;TOPIC_ID=13806" target="_blank">Centers for Disease Control and Prevention</a>. Sharing of personal items such as towels, drinks, and sporting equipment should be discouraged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An athlete with infection should be isolated from team members and the general public when possible. This includes during meals, transport, and for competitions, at both accommodations and sporting venues. Some teams and sporting groups organize spare accommodations and separate meal rooms from the general public. </p><p></p><p class="headingAnchor" id="H621675074"><span class="h3">Influenza</span><span class="headingEndMark"> — </span>Influenza infections are highly contagious and can spread quickly through a team's roster if left unattended. We test for influenza in athletes with an influenza-like illness who participate in competitive team sports. Rapid point-of-care analyzers can be used for this process [<a href="#rid29">29</a>]. If an athlete tests positive for influenza, prophylaxis for close contacts, particularly during competitions, may be reasonable to prevent further spread of the disease [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/132409.html" rel="external">"Seasonal influenza in children: Prevention with antiviral drugs"</a> and  <a class="medical medical_review" href="/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a> and  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p>Those athletes with influenza should be isolated from others on the team and only allowed to return to participation after symptom resolution. The athlete must be afebrile off antipyretics for a minimum of one day, well-hydrated, and free of any myalgias or systemic symptoms. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Infection control and returning to work/school'</a>.)</p><p>Once an index influenza case has been confirmed, it remains important to test subsequent cases for both influenza and SARS-CoV-2, as symptoms are similar. Athletes should receive the influenza and COVID-19 vaccines to minimize the risks posed by these illnesses. (See <a class="local">'Immunizations'</a> below.)</p><p class="headingAnchor" id="H2950337541"><span class="h3">COVID-19</span><span class="headingEndMark"> — </span>The presentation and management of athletes infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not differ from the general population and are reviewed in detail in several topics, including those that follow. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="headingAnchor" id="H621675243"><span class="h3">Pertussis</span><span class="headingEndMark"> — </span>For athletes with confirmed pertussis, we agree with the American College of Chest Physicians recommendations that they be isolated for the first five days of antibiotic treatment [<a href="#rid31">31</a>]. Teammates and coaches should receive post-exposure prophylaxis. (See  <a class="medical medical_review" href="/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/8045.html" rel="external">"Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H92871608"><span class="h2">Immunizations</span><span class="headingEndMark"> — </span>Immunizations schedules should typically follow recommendations for the general population. For athletes, the timing of vaccine administration should be planned with the goal of minimizing any adverse effect on training and competition [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults", section on 'Immunization schedule for nonpregnant adults'</a>.)</p><p>When possible, vaccines should be administered at the onset of a rest period from training and competition [<a href="#rid32">32,33</a>]. If vaccination within a training and/or competition period cannot be avoided, we administer the vaccine shortly after a competition to provide as long of a period of time until the next competition as possible. After immunizations, exercise intensity should be transiently decreased if an athlete feels unwell, or is inconvenienced by pain and soreness at or around the injection site. Side effects from inactivated vaccines can be expected within the first two days after vaccination, while side effects are typically seen approximately 10 to 14 days after receiving live attenuated vaccines [<a href="#rid33">33</a>].</p><p>It is essential to know the athlete's travel schedule during the season. Early preparation will allow time for the athlete to be immunized as appropriate. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel"</a>.)</p><p class="headingAnchor" id="H92872284"><span class="h2">Overtraining syndrome</span><span class="headingEndMark"> — </span>Almost every athlete feels the effects of fatigue at some point in training and competition. However, some athletes may develop overtraining syndrome, which can lead to recurrent respiratory infections. Measures to prevent overtraining syndrome are discussed separately. (See  <a class="medical medical_review" href="/d/html/97059.html" rel="external">"Overtraining syndrome in athletes", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/d/html/97059.html" rel="external">"Overtraining syndrome in athletes", section on 'Prevention measures'</a>.).</p><p class="headingAnchor" id="H92871693"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Immune function can be compromised with micronutrient deficiencies (eg, zinc) in the general population, but this is less likely in trained athletes who consume a well-balanced diet. Some athletes struggle to maintain good dietary practices, and may benefit from nutritional supplementation [<a href="#rid34">34</a>]. However, adolescent athletes in particular may have limited or inaccurate knowledge and information about supplements [<a href="#rid35">35</a>]. Dietary review with a registered dietitian is useful in identifying athletes with poor dietary practices, and in developing sports-specific strategies. (See  <a class="medical medical_review" href="/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Deficiency'</a>.)</p><p>There is little evidence to support the use of nutritional supplements (eg, vitamin supplements or probiotics) in preventing URTI in athletes [<a href="#rid36">36</a>]. Additionally, supplements may be contaminated with banned substances. (See  <a class="medical medical_review" href="/d/html/6868.html" rel="external">"The common cold in adults: Treatment and prevention", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H20838793"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Upper respiratory tract infections (URTIs) are the most common type of infection among athletes. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of athletes for the various etiologies of upper respiratory tract infections (URTIs) is the same as for the general population. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – In general, treatment strategies and medications for upper respiratory tract illnesses in athletes should be the same as for nonathletes. There are some specific considerations for athletes regarding choice of antibiotics and medications used for symptom relief  (<a class="graphic graphic_table graphicRef102914" href="/d/graphic/102914.html" rel="external">table 1</a>). (See <a class="local">'Antibiotics'</a> above and <a class="local">'Medications used for symptom relief'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Return to play</strong> – Athletes with mild viral URTIs not involving highly contagious or dangerous pathogens can continue to play and compete if they feel able  (<a class="graphic graphic_algorithm graphicRef103349" href="/d/graphic/103349.html" rel="external">algorithm 1</a>). Athletes with pre-existing conditions and/or moderate to severe illness (fever or systemic symptoms) may need to refrain from play until such symptoms have resolved. There may be particular considerations for return to play in certain situations. (See <a class="local">'General participation'</a> above and <a class="local">'Special circumstances'</a> above and <a class="local">'Influenza'</a> above and <a class="local">'Pertussis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mountjoy M, Junge A, Alonso JM, et al. Sports injuries and illnesses in the 2009 FINA World Championships (Aquatics). Br J Sports Med 2010; 44:522.</a></li><li><a class="nounderline abstract_t">Edouard P, Junge A, Sorg M, et al. Illnesses during 11 international athletics championships between 2009 and 2017: incidence, characteristics and sex-specific and discipline-specific differences. Br J Sports Med 2019; 53:1174.</a></li><li><a class="nounderline abstract_t">Jaworski CA, Rygiel V. Acute Illness in the Athlete. Clin Sports Med 2019; 38:577.</a></li><li><a class="nounderline abstract_t">Engebretsen L, Soligard T, Steffen K, et al. Sports injuries and illnesses during the London Summer Olympic Games 2012. Br J Sports Med 2013; 47:407.</a></li><li><a class="nounderline abstract_t">Soligard T, Steffen K, Palmer-Green D, et al. Sports injuries and illnesses in the Sochi 2014 Olympic Winter Games. Br J Sports Med 2015; 49:441.</a></li><li><a class="nounderline abstract_t">Hellard P, Avalos M, Guimaraes F, et al. Training-related risk of common illnesses in elite swimmers over a 4-yr period. Med Sci Sports Exerc 2015; 47:698.</a></li><li><a class="nounderline abstract_t">Derman W, Badenhorst M, Eken M, et al. Risk factors associated with acute respiratory illnesses in athletes: a systematic review by a subgroup of the IOC consensus on 'acute respiratory illness in the athlete'. Br J Sports Med 2022; 56:639.</a></li><li><a class="nounderline abstract_t">Schwellnus M, Soligard T, Alonso JM, et al. How much is too much? (Part 2) International Olympic Committee consensus statement on load in sport and risk of illness. Br J Sports Med 2016; 50:1043.</a></li><li><a class="nounderline abstract_t">Walsh NP. Recommendations to maintain immune health in athletes. Eur J Sport Sci 2018; 18:820.</a></li><li><a class="nounderline abstract_t">Simpson RJ, Campbell JP, Gleeson M, et al. Can exercise affect immune function to increase susceptibility to infection? Exerc Immunol Rev 2020; 26:8.</a></li><li><a class="nounderline abstract_t">Kaulback K, Pyne DB, Hull JH, et al. The effects of acute respiratory illness on exercise and sports performance outcomes in athletes - A systematic review by a subgroup of the IOC consensus group on "Acute respiratory illness in the athlete". Eur J Sport Sci 2023; 23:1356.</a></li><li><a class="nounderline abstract_t">Ekblom B, Ekblom O, Malm C. Infectious episodes before and after a marathon race. Scand J Med Sci Sports 2006; 16:287.</a></li><li><a class="nounderline abstract_t">Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of Immune Functions. Prog Mol Biol Transl Sci 2015; 135:355.</a></li><li><a class="nounderline abstract_t">Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc 1994; 26:128.</a></li><li><a class="nounderline abstract_t">Kakanis MW, Peake J, Brenu EW, et al. The open window of susceptibility to infection after acute exercise in healthy young male elite athletes. Exerc Immunol Rev 2010; 16:119.</a></li><li><a class="nounderline abstract_t">Pyne DB, Hopkins WG, Batterham AM, et al. Characterising the individual performance responses to mild illness in international swimmers. Br J Sports Med 2005; 39:752.</a></li><li><a class="nounderline abstract_t">Horn PL, Pyne DB, Hopkins WG, Barnes CJ. Lower white blood cell counts in elite athletes training for highly aerobic sports. Eur J Appl Physiol 2010; 110:925.</a></li><li><a class="nounderline abstract_t">Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 2014; 49:422.</a></li><li><a class="nounderline abstract_t">Fayock K, Voltz M, Sandella B, et al. Antibiotic precautions in athletes. Sports Health 2014; 6:321.</a></li><li class="breakAll">WADA Prohibited List. http://list.wada-ama.org/ (Accessed on September 26, 2021).</li><li class="breakAll">2020-21 NCAA Banned Substances. Available at: http://www.ncaa.org/sport-science-institute/topics/2020-21-ncaa-banned-substances (Accessed on September 26, 2021).</li><li><a class="nounderline abstract_t">Metz JP. Upper respiratory tract infections: who plays, who sits? Curr Sports Med Rep 2003; 2:84.</a></li><li><a class="nounderline abstract_t">Hoffman MD, Cotter JD, Goulet ÉD, Laursen PB. VIEW: Is Drinking to Thirst Adequate to Appropriately Maintain Hydration Status During Prolonged Endurance Exercise? Yes. Wilderness Environ Med 2016; 27:192.</a></li><li><a class="nounderline abstract_t">Eichner E. Eichner, E. Infection, immunity, and exercise. What to tell patients? Phys Sportsmed 1993; 21:125.</a></li><li><a class="nounderline abstract_t">Jansen van Rensburg A, Janse van Rensburg DCC, Schwellnus MP, et al. Days until return-to-play differ for sub-categories of acute respiratory tract illness in Super Rugby players: A cross-sectional study over 5 seasons (102,738 player-days). J Sci Med Sport 2021; 24:1218.</a></li><li class="breakAll">Divers Alert Network. http://diversalertnetwork.org/medical. (Accessed on September 26, 2021).</li><li class="breakAll">Bove A. Medical evaluation for sport diving. In: Diving Medicine, 4th ed, Bove A, Davis J (Eds), Saunders, Philadelphia 2004. p.519.</li><li><a class="nounderline abstract_t">Schwellnus M, Janse van Rensburg C, Bayne H, et al. Team illness prevention strategy (TIPS) is associated with a 59% reduction in acute illness during the Super Rugby tournament: a control-intervention study over 7 seasons involving 126 850 player days. Br J Sports Med 2020; 54:245.</a></li><li><a class="nounderline abstract_t">Tsalik EL, Henao R, Montgomery JL, et al. Discriminating Bacterial and Viral Infection Using a Rapid Host Gene Expression Test. Crit Care Med 2021; 49:1651.</a></li><li><a class="nounderline abstract_t">Gundlapalli AV, Rubin MA, Samore MH, et al. Influenza, Winter Olympiad, 2002. Emerg Infect Dis 2006; 12:144.</a></li><li><a class="nounderline abstract_t">Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:1S.</a></li><li><a class="nounderline abstract_t">Hull JH, Schwellnus MP, Pyne DB, Shah A. COVID-19 vaccination in athletes: ready, set, go…. Lancet Respir Med 2021; 9:455.</a></li><li><a class="nounderline abstract_t">Gärtner BC, Meyer T. Vaccination in elite athletes. Sports Med 2014; 44:1361.</a></li><li><a class="nounderline abstract_t">Pyne DB, Verhagen EA, Mountjoy M. Nutrition, illness, and injury in aquatic sports. Int J Sport Nutr Exerc Metab 2014; 24:460.</a></li><li><a class="nounderline abstract_t">Mettler S, Lehner G, Morgan G. Widespread Supplement Intake and Use of Poor Quality Information in Elite Adolescent Swiss Athletes. Int J Sport Nutr Exerc Metab 2022; 32:41.</a></li><li><a class="nounderline abstract_t">Walsh NP, Gleeson M, Pyne DB, et al. Position statement. Part two: Maintaining immune health. Exerc Immunol Rev 2011; 17:64.</a></li></ol></div><div id="topicVersionRevision">Topic 13806 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460256" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sports injuries and illnesses in the 2009 FINA World Championships (Aquatics).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30862705" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Illnesses during 11 international athletics championships between 2009 and 2017: incidence, characteristics and sex-specific and discipline-specific differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31472768" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute Illness in the Athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515712" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sports injuries and illnesses during the London Summer Olympic Games 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631542" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sports injuries and illnesses in the Sochi 2014 Olympic Winter Games.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100341" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Training-related risk of common illnesses in elite swimmers over a 4-yr period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35277393" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors associated with acute respiratory illnesses in athletes: a systematic review by a subgroup of the IOC consensus on 'acute respiratory illness in the athlete'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535991" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How much is too much? (Part 2) International Olympic Committee consensus statement on load in sport and risk of illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29637836" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recommendations to maintain immune health in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139352" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Can exercise affect immune function to increase susceptibility to infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35695464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effects of acute respiratory illness on exercise and sports performance outcomes in athletes - A systematic review by a subgroup of the IOC consensus group on "Acute respiratory illness in the athlete".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16895535" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Infectious episodes before and after a marathon race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26477922" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Exercise and the Regulation of Immune Functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164529" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Exercise, upper respiratory tract infection, and the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839496" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The open window of susceptibility to infection after acute exercise in healthy young male elite athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183773" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Characterising the individual performance responses to mild illness in international swimmers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20640439" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lower white blood cell counts in elite athletes training for highly aerobic sports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24762232" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982704" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic precautions in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982704" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibiotic precautions in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982704" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotic precautions in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12831664" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Upper respiratory tract infections: who plays, who sits?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27291699" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : VIEW: Is Drinking to Thirst Adequate to Appropriately Maintain Hydration Status During Prolonged Endurance Exercise? Yes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Eichner, E. Infection, immunity, and exercise. What to tell patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246554" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Days until return-to-play differ for sub-categories of acute respiratory tract illness in Super Rugby players: A cross-sectional study over 5 seasons (102,738 player-days).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246554" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Days until return-to-play differ for sub-categories of acute respiratory tract illness in Super Rugby players: A cross-sectional study over 5 seasons (102,738 player-days).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246554" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Days until return-to-play differ for sub-categories of acute respiratory tract illness in Super Rugby players: A cross-sectional study over 5 seasons (102,738 player-days).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31371338" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Team illness prevention strategy (TIPS) is associated with a 59% reduction in acute illness during the Super Rugby tournament: a control-intervention study over 7 seasons involving 126 850 player days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33938716" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Discriminating Bacterial and Viral Infection Using a Rapid Host Gene Expression Test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16494733" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influenza, Winter Olympiad, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428686" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33556316" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : COVID-19 vaccination in athletes: ready, set, go….</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24986118" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vaccination in elite athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937101" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nutrition, illness, and injury in aquatic sports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34552032" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Widespread Supplement Intake and Use of Poor Quality Information in Elite Adolescent Swiss Athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446353" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Position statement. Part two: Maintaining immune health.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
